Jinling Pharmaceutical Company Limited (SHE:000919)
China flag China · Delayed Price · Currency is CNY
6.07
-0.14 (-2.25%)
Nov 13, 2026, 3:04 PM CST

SHE:000919 Balance Sheet

Millions CNY. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Cash & Equivalents
1,4641,5171,7711,5481,4951,502
Short-Term Investments
-393.03165.22337.45250-
Trading Asset Securities
1,185939.31706.05233.8692.351.25
Cash & Short-Term Investments
2,6492,8492,6422,1191,8371,503
Cash Growth
3.49%7.84%24.69%15.33%22.25%14.12%
Accounts Receivable
647.9690.95686.73591.05467.22507.2
Other Receivables
4.9713.798.168.7653.1216.85
Receivables
652.87704.74694.89599.81520.34524.05
Inventory
229.6233.14271.62290.91250.48245.48
Prepaid Expenses
---0.151.16-
Other Current Assets
25.6610.529.379.6323.7916.29
Total Current Assets
3,5573,7983,6183,0202,6332,289
Property, Plant & Equipment
1,4481,4571,5011,5411,3031,297
Long-Term Investments
61.91211.37431.07369.32265.01638.97
Goodwill
44.3744.3762.42148.7227.3318.05
Other Intangible Assets
306.88322.93325.67341.67258.44140.2
Long-Term Deferred Tax Assets
13.0912.6112.4916.6128.5419.62
Long-Term Deferred Charges
111.51120.5583.3413.9418.2617.85
Other Long-Term Assets
497.0640.3154.494210.726.96
Total Assets
6,0406,0076,0895,4934,5444,448

Liabilities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Accounts Payable
558.3554.97595.31546.69454.04479.36
Accrued Expenses
156.45222.28212.46224.73219.95207.27
Short-Term Debt
----1.4815.01
Current Portion of Leases
8.748.744.233.081.531.06
Current Income Taxes Payable
-32.3735.5337.9748.3843.09
Current Unearned Revenue
19.8119.5735.617.6522.1426.9
Other Current Liabilities
261.12138.03143.9182.53117.983.25
Total Current Liabilities
1,004975.951,0271,013865.42855.95
Long-Term Debt
150.09150.1150.12---
Long-Term Leases
33.5832.9834.8538.62.290.59
Long-Term Unearned Revenue
3.380.6810.470.630.79
Long-Term Deferred Tax Liabilities
21.6425.0127.2828.7248.9855.77
Total Liabilities
1,2131,1851,2401,080917.32913.1

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Common Stock
621.92621.92623.71511.14510.4504
Additional Paid-In Capital
1,0881,0881,098651.74478.34462.06
Retained Earnings
2,0622,0652,0732,0952,0251,958
Treasury Stock
---6.77-26.99-23.62-
Comprehensive Income & Other
2.672.663.093.424.173.29
Total Common Equity
3,7753,7783,7913,2342,9942,928
Minority Interest
1,0521,0441,0571,178632.88606.84
Shareholders' Equity
4,8274,8224,8494,4123,6273,535
Total Liabilities & Equity
6,0406,0076,0895,4934,5444,448

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Total Debt
192.4191.82189.2141.675.316.66
Net Cash (Debt)
2,4572,6582,4532,0771,8321,486
Net Cash Growth
3.69%8.34%18.08%13.39%23.26%12.85%
Net Cash Per Share
3.954.274.144.123.642.95
Filing Date Shares Outstanding
621.92621.92623.71629.06488.88510.4
Total Common Shares Outstanding
621.92621.92623.71511.14488.88504
Working Capital
2,5532,8222,5912,0071,7681,433
Book Value Per Share
6.076.076.086.336.125.81
Tangible Book Value
3,4233,4103,4032,7442,7082,769
Tangible Book Value Per Share
5.505.485.465.375.545.50
Buildings
-1,5101,4951,5071,2941,274
Machinery
-1,4981,4161,3491,1141,074
Construction In Progress
-48.1671.7884.237.8428.78